Cost-effectiveness of community-based interventions for type 2 diabetes management in Indonesia: a time-horizon sensitivity analysis [0.03%]
基于社区的2型糖尿病综合干预措施的成本效果分析：时间维度敏感性分析
Aalbrecht A Irawan,Nursanti Anggriani,Yudhie Andriyana et al.
Aalbrecht A Irawan et al.
Background: Type 2 Diabetes Mellitus (T2DM) imposes a severe economic burden on Indonesia's Social Health Insurance Administration Body (BPJS Kesehatan), driven predominantly by expensive late-stage complications. While t...
The economic impact of medical scribe provision on physician productivity in outpatient clinics: a scoping review [0.03%]
门诊医疗记录员的提供对医师生产力的经济影响：一项范围评价研究
Ashwag Al Dhuhaibat,Thomas Mason,Erik Koornneef
Ashwag Al Dhuhaibat
Background: Medical scribes are increasingly used in outpatient clinics in the United States to reduce physician documentation burden, but their economic and operational impact remains inconsistently characterized. This s...
The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany [0.03%]
德国二线降糖药联合标准疗法预防2型糖尿病肾病的成本效益分析
Hanni Hille,Wendelin Schramm,Ahmed Bounekkar
Hanni Hille
Background: Type 2 diabetes and its associated complications like nephropathy impose a serious burden on health systems. Several blood glucose-lowering medications have shown to be likely to provide nephroprotective prope...
Cost-effectiveness analysis of molecular reflex testing-based targeted therapy in non-small cell lung cancer from a German healthcare payer perspective using a decision tree model [0.03%]
基于决策树模型的德国医疗支付人视角下的非小细胞肺癌分子反射检测靶向治疗的成本效益分析
Leonie Schumacher,Melina Sophie Kurte,Tabea Poos et al.
Leonie Schumacher et al.
Background: Reflex testing (RT) - pathologist-initiated molecular testing performed at non-small cell lung cancer (NSCLC) diagnosis - enables rapid identification of actionable genomic alterations for targeted therapy (TT...
Cost-effective primary health-centre allocation in Himalayan terrain: a spatial and resource-allocation analysis of Chamoli and Rudraprayag districts, India [0.03%]
喜马拉雅山区低成本初级卫生中心分配：印度查莫利和鲁德普拉亚格地区的空间和资源配置分析
Neelkamal Alomayan Kalita,Guru Vasishtha
Neelkamal Alomayan Kalita
Background: Primary Health Centre (PHC) coverage in Himalayan India is constrained by terrain, dispersed settlement and a population-based norm (one PHC per 20,000 in hilly areas) that treats elevation as exogenous. Exist...
Cost-effectiveness analysis of bacterial vaginosis screening strategies in women attempting for natural conception [0.03%]
自然受孕妇女细菌性阴道病筛查策略的成本效益分析
Dengyan Qi,Hanyue Zheng,Mengjie Zhao et al.
Dengyan Qi et al.
Objectives: Bacterial vaginosis (BV) is associated with reduced fecundability in women. To address the limited accessibility and diagnostic sensitivity of current preconception BV screening in China, this study evaluated ...
Cost-effectiveness of luseogliflozin for the management of type 2 diabetes mellitus in Vietnam: a Markov model analysis from the Vietnam social health insurance perspective [0.03%]
卢格列净治疗2型糖尿病的成本效益分析：从越南社会保险角度出发的马尔可夫模型分析
The Due Ong,Anh Son Dao,Quoc Trung Ly et al.
The Due Ong et al.
Aim: This study aimed to assess the cost-utility of luseogliflozin compared with Standard of Care (SoC) for patients with T2DM in Vietnam, under two reimbursement scenarios by Vietnam Social Health Insurance (VSHI). ...
Unintended consequences of National centralized volume-based drug procurement policy in China: a game theory-based analytical approach for pharmaceutical quality and pricing [0.03%]
基于博弈论的我国国家集中带量采购政策的意外后果分析——兼论药品质量和价格问题
Siyu Zhang,Jiaxue Li,Siming Li et al.
Siyu Zhang et al.
Background: The pharmaceutical industry plays a pivotal role in the healthcare economy, with drug quality and pricing being critical to consumer welfare. China's government has implemented National centralized volume-base...
Real-world cost avoidance associated with bevacizumab biosimilar adoption in a tertiary public hospital in Ecuador: a cost-minimization and budget impact analysis [0.03%]
贝伐单抗类似药在厄瓜多尔一家三级公立医院应用的成本避免和预算影响分析
Sara Rodríguez,Carla Arias,María Del Carmen Aynaguano et al.
Sara Rodríguez et al.
Background: The increasing use of high-cost oncology therapies poses significant challenges for healthcare systems, particularly in low- and middle-income countries. The introduction of biosimilars offers a potential stra...
A systematic review of the cost-utility of dapagliflozin for managing chronic kidney disease [0.03%]
达格列净治疗慢性肾脏疾病的成本效益系统综述
Ronald Watema-Lord,Feng Xie,Chiranjeev Sanyal
Ronald Watema-Lord
Background: Chronic kidney disease (CKD) is a significant public health concern. Dapagliflozin has been demonstrated to improve the quality of life for patients with CKD. This systematic review aimed to summarize the avai...